Ranexa is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).
Prescribing Information
Product Information
Product Overview
Patient Materials
Product Information
- Product Name: Ranexa                    Â
- Molecule: Ranolazine                   Â
- Posology: Ranexa is available as 375mg, 500mg, and 750mg prolonged-release tablets.
- Dosing: The recommended initial dose of Ranexa is 375mg twice daily. After 2–4 weeks, the dose should be titrated to 500mg twice daily and, according to the patient’s response, further titrated to a recommended maximum dose of 750mg twice daily.
Prescribing Information

Product Overview

Â
Â
Patient Materials
Below are some resources that A.Menarini Ireland have assisted to develop:
Irish Heart Foundation Cardiac Rehab for All Programme website
Irish Heart Foundation Cardiac Rehab for All Programme Patient Booklet
Â
Â





